SFDA Speeds Up Release Of Vaccines To Quake-Hit Regions
This article was originally published in PharmAsia News
Executive Summary
Due to the urgent needs of earthquake victims, China's State FDA has, for the second time, adjusted the procedure for release of blood products and vaccines to speed up the distribution of relief supplies. SFDA and vaccine manufacturers will synchronize the quality inspection and approval of badly needed vaccine and blood products that have been produced but are awaiting approval, as well as products still being churned out. These include tetanus immunoglobulin, human albumin, cholera toxin B subunit vaccine, hepatitis A vaccine, Japanese B encephalitis vaccine, diphtheria and tetanus combined vaccine, tetanus vaccine and hemorrhagic fever vaccine. (Click here for more - Chinese Language)
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.